Patient outcomes do not appear to be negatively impacted by these risks, researchers noted. The new data were presented at Heart Rhythm 2025 and published in JACC: Clinical Electrophysiology.

The study's authors reviewed CCTA imaging results taken before and after radiotherapy, evaluating each image for signs of coronary calcification and inflammation. 

An advanced preservation system from Paragonix, a Getinge company, was linked to dramatic reductions in both mortality and procedural complications. 

Researchers explored the potential impact of more than 100 risk factors on a person's risk of sudden cardiac arrest. Some of their findings were what you may expect, but others were much more surprising.

Partho Sengupta, MD, shared his perspective on the current state of artificial intelligence in cardiology. The technology continues to evolve, he said, though it does still face certain limitations.

New data published in JACC represents another big win for Bayer's finerenone. The drug has previously been linked to cardiovascular benefits for patients with CKD and heart failure, but its potential across the full CKM spectrum remained a bit of a mystery.

We asked readers to nominate individuals who are already making a major impact on the world of cardiovascular health at a young age. We wanted to hear about your best, your brightest, your most radical thinkers; the people who are never satisfied by something being “good enough” or “how it’s always been done.” 

Real-world patients were still associated with "excellent" outcomes, but it is important for cardiologists and patients alike to know as much as possible about the odds of survival following treatment. 

The name and employer of a doctor accused of sexually and physically abusing multiple women is no longer being kept from the public. He faces a total of 20 charges, entering a plea of not guilty to all of them. 

New research may help providers identify patterns on neuroimaging that could offer clues into how well patients are responding to antidepressant medications.

Healthcare may finally have struck a healthy balance between AI hype and AI reality, according to a report from impartial observers who are also, indirectly at least, healthcare AI stakeholders.